CFX Colfax Corporation

Colfax Completes Sale of Air & Gas Handling Business

Colfax Completes Sale of Air & Gas Handling Business

Annapolis Junction, MD, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax”) (NYSE: CFX), a leading diversified industrial technology company, today announced it completed the sale of its Air & Gas Handling business to an affiliate of KPS Capital Partners, LP for an aggregate consideration of $1.8 billion. The cash proceeds, net of transaction expenses and estimated taxes, of approximately $1.6 billion will be used to pay down debt. 

“Colfax has built a much stronger portfolio - less cyclical, higher margin, and with more stable cash generation and an attractive long-term growth outlook,” said Matt Trerotola, Colfax President and CEO.  “This is a terrific foundation on which to drive continuous improvement and compound our results by investing in innovation and attractive acquisitions.”   

ABOUT COLFAX CORPORATION

Colfax Corporation is a leading diversified technology company that provides orthopedic care and fabrication technology products and services to customers around the world principally under the DJO and ESAB brands.  Colfax believes that its brands are among the most highly recognized in each of the markets that it serves. Colfax is traded on the NYSE under the ticker “CFX.”  Additional information about Colfax is available at .

Terry Ross, Vice President
Colfax Corporation
+1 (301) 323-9090
 
EN
30/09/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Colfax Corporation

Moody's withdraws Colfax Corporation's ratings, including the Ba2 seni...

Moody's Investors Service (Moody's) has withdrawn all ratings on Colfax Corporation (Colfax) including the Ba2 corporate family rating, the Ba2-PD probability of default rating, the Ba2 senior unsecured rating and the SGL-2 Speculative Grade Liquidity Rating. The stable outlook was also withdrawn. ...

 PRESS RELEASE

Enovis (formerly Colfax) Completes Spin-off of ESAB Corporation

Enovis (formerly Colfax) Completes Spin-off of ESAB Corporation Wilmington, DE, April 05, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (“Enovis” or the “Company”) (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, announced today the completion of its previously announced separation (the “Separation”) of its fabrication technology business into an independent, publicly traded company, ESAB Corporation (“ESAB”) (NYSE: ESAB). Immediately following the Separation, Enovis effected its previously announced reverse stock split of all issued...

 PRESS RELEASE

Colfax Announces Board of Directors for Post-Spinoff ESAB

Colfax Announces Board of Directors for Post-Spinoff ESAB Wilmington, DE, March 28, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company which will renamed Enovis Corporation (“Enovis”) following the expected April 4, 2022 consummation of the Company’s previously announced spin-off of its fabrication technology business (the “Separation"), which will operate as ESAB Corporation (“ESAB”) after the Separation, today announced the future composition of the full ESAB Board of Directors (the “Board”). Following the Separation, Mitchell P. Rales ...

 PRESS RELEASE

Colfax Announces Expected Completion Date of April 4, 2022 for Spin-Of...

Colfax Announces Expected Completion Date of April 4, 2022 for Spin-Off of ESAB Corporation “When-issued” trading of ESAB and Colfax ex-distribution common stock expected to begin on March 21, 2022Record date for distribution of ESAB common stock will be March 22, 2022Distribution Date expected to be April 4, 2022 Wilmington DE,, March 14, 2022 (GLOBE NEWSWIRE) -- —Colfax Corporation (“Colfax”) (NYSE: CFX) today announced that its Board of Directors has declared (a) a pro rata distribution of 90% of the outstanding common stock of ESAB Corporation (“ESAB”) to Colfax shareholders of recor...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch